Samba BioLogics Selected for NIH-sponsored DRIVEN Program
Samba BioLogics, Inc. was selected for the NIH-sponsored DRIVEN Program to commercialize our biologics + IP (incubator at Celdara Medical, LLC; West Lebanon, New Hampshire).
ABOUT DRIVEN
The DRIVEN Accelerator Hub is an NIH-funded consortium led by Celdara Medical and Simbex in partnership with leading research institutions in the Northeast, including Brown University, Dartmouth College, Maine Medical Center, MDI Biological Laboratory, the University of Delaware, the University of New Hampshire, the University of Rhode Island, and the University of Vermont. DRIVEN has assembled an External Advisory Committee (EAC) comprised exclusively of investors (representing over $120B in AUM) and buy-side business development leaders (cumulative market cap exceeding $1T). DRIVEN was supported by NIGMS UT2GM130176. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
VasaPlex Featured on WCAX-TV
On August 10, 2016, Jeffrey Spees, PH.D., associate professor in the Division of Cardiovascular Medicine, was featured in a story on WCAX-TV regarding the drug therapy he’s developing, called VasaPlex, that has been shown in animal models to help reduce heart damage following a heart attack.